macitentan 10 mg Clinical Research Trials | TrialX

Loading...

Please select a valid location from the dropdown

Filter By

Clear all Advanced

Advanced Filters

Gender
Phase
Study Type
Sponsors
Accepts healthy volunteers
Online Trials
Age Group

Any (1)

Phase 3 (1)

Interventional (1)

Actelion (1)

No (1)

No (1)

Adult (18+) (1)

I am/have/had

I am/have/hadconnective tissue disease

I am/have/hadHIV Infection

I am/have/hadventricular septal defects

I am/have/hadpatent ductus arteriosus

I am/have/hadright heart catheterization

I am/have/hadatrial septal defect

I am/have/hadseptal defect

I am/have/hadventricular septal defect

I am/have/hadleft ventricular end-diastolic pressure

I am/have/hadhypertension

I am/have/hadhemodynamic evaluation

I am/have/hadheart disease

added new label for I am/have/had

more

I am looking for

I am looking formacitentan 10 mg

I am looking formacitentan

added new label for I am looking for

more

Advanced Filters

Loading...

Found 1 clinical trials

We call this “infoimagery”. It is unique to every trial and is generated based on a trials specific data eg. therapeutic area, study type, phase etc. and the centerwatch system associates the information to a matching set of related symbols and icons.

What's this?

Multi-country trial
Phase 3
For Seniors
For adults
Recruiting in 100s
Interventional Study
all
Recruiting

Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension

The purpose of this study is to demonstrate superiority of macitentan 75 milligrams (mg) in prolonging the time to the first clinical events committee (CEC)-adjudicated morbidity or mortality (M/M) event in participants with symptomatic pulmonary arterial hypertension (PAH) compared to macitentan 10 mg.

hemodynamic evaluation

connective tissue disease

macitentan

HIV Infection

ventricular septal defects

0 views
19 Feb, 2024

Congrats! You have your own personal workspace now.

Learn more

© Copyright TrialX 2024 All rights reserved.